{"transactions":[{"id":905414,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-13T17:19:32.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":124000,"derivative":{"exercise_price":16.71,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0002008707-26-000001","document":"wk-form4_1771021170.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000200870726000001/wk-form4_1771021170.xml","form_type":"4"}},{"id":1090773,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090772,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":76000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":76000,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090771,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090770,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":73000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":73000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090769,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":123645,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.3,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":123645},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090768,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":123645,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":123645,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":123645},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090767,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33008,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33008},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090766,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":33008,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":33008,"derivative":{"exercise_price":2.35,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33008},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090765,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22481,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":22481},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090764,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":22481,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":22481,"derivative":{"exercise_price":2.35,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":22481},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1278951,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-07T16:21:55.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":76000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000014","document":"wk-form4_1738963307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000014/wk-form4_1738963307.xml","form_type":"4"}},{"id":1456364,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-10","kind":"purchase","planned":false,"acquired":true,"shares":2931,"price":13.22,"value":38747.82,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.04 to $13.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":39851,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1456363,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":1388,"price":13.15,"value":18252.2,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":36920,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1456362,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":10681,"price":12.53,"value":133832.93,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":35532,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1597829,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-05T18:00:40.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":73000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":73000,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001415889-24-006824","document":"form4-03052024_060306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924006824/form4-03052024_060306.xml","form_type":"4"}},{"id":1655527,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Series B Preferred Stock","published_at":"2024-02-07T16:38:06.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":16666,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7851},"source":{"system":"sec-edgar","filing":"0001415889-24-002936","document":"form4-02072024_090257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924002936/form4-02072024_090257.xml","form_type":"4"}},{"id":1655526,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-07T16:38:06.000Z","date":"2024-02-06","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":16,"value":272000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":24851,"source":{"system":"sec-edgar","filing":"0001415889-24-002936","document":"form4-02072024_090257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924002936/form4-02072024_090257.xml","form_type":"4"}},{"id":1655525,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-07T16:38:06.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":7851,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":7851,"source":{"system":"sec-edgar","filing":"0001415889-24-002936","document":"form4-02072024_090257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924002936/form4-02072024_090257.xml","form_type":"4"}}]}